Keohane et al. showed in myelofibrosis, PV, or ET patients receiving either ruxolitinib or fedratinib a significant decrease of cytokines after the first month (IFNα, IFNγ, IL10, IL2R, IL4, and IL17) but a weak rise in cytokine levels after six months [48]. Here, IFNG is linked to acquired polycythemia vera.